U. S. Food and Drug Administration has approved the blood-thinning drug Plavix to be available in generic versions in pharmacies, a report has revealed.
The application for the drug’s, with generic name clopidogrel, generic application was given by Pittsburgh-based Mylan Pharmaceuticals at first. According to the same, it will be the only one to sell the generic version in the market.
The drug is meant for those who either have a heart disease or have a family history of strokes and heart disease and want to avoid clotting problems and further risks.
It has been found that the drug was previously marketed by Sanofi-Aventis in collaboration with Bristol-Myers Squibb. A total of $6.7 billion for the last year has been made by its US sales, as per the findings.
The FDA has set different levels of dosage of the drug to be supplied by different pharmaceutical companies. It is being said that Dr. Reddy’s Laboratories, Gate Pharmaceuticals and Mylan along with Teva Pharmaceuticals would sell 300-milligram tablets of clopidogrel. And Aurobindo Pharma, Mylan, Roxane Laboratories, Teva and some others would sell the 75-milligram dosage.
- Key Interest Rates Unaltered and Mortgages Get Cheaper
- November Home Sale Prices Moved up in November by 5.3 Percent
- Hyatt’s Malware Attack Affects Properties in India too
- London’s Expensive Property Market Advertises Cheapest Flat for about £75,000
- Slow Down in Housing Market Could be a Drag on Canada’s Economy
- Record Profit for American Airlines in 2015
- Soft Patch for the U.S. Economy in 2015, Q4 with Inventory Stockpile and Slowing Global Demand
- Oil Futures Scale on Hopes of Reduced Supply as Russia Plans to Talk to OPEC Members
- Amazon’s Quarterly Result Misses Expectations; Shares Drop
- Social media to blame for sleep disturbances, study